Smyth2
Bluelighter
- Joined
- Jul 26, 2011
- Messages
- 436
Blixeprodil
(2R)-2-(4-Fluorophenyl)-2-(methylamino)cyclohexan-1-one
GM-1020 or as (R)-4-fluorodeschloroketamine ((R)-4-FDCK),
[2881017-49-6]

Klein AK, Austin EW, Cunningham MJ, Dvorak D, Gatti S, Hulls SK, Kiss L, Kruegel AC, Marek GJ, Papp M, Sporn J, Hughes ZA. GM-1020: a novel, orally bioavailable NMDA receptor antagonist with rapid and robust antidepressant-like effects at well-tolerated doses in rodents. Neuropsychopharmacology. 2024 May;49(6):905-914. doi: 10.1038/s41386-023-01783-1. Epub 2024 Jan 4. PMID: 38177696; PMCID: PMC11039472.
Andrew Carry Kruegel, WO2021134086 (to Gilgamesh Pharmaceuticals Inc, Columbia University in the City of New York).
(2R)-2-(4-Fluorophenyl)-2-(methylamino)cyclohexan-1-one
GM-1020 or as (R)-4-fluorodeschloroketamine ((R)-4-FDCK),
[2881017-49-6]

Klein AK, Austin EW, Cunningham MJ, Dvorak D, Gatti S, Hulls SK, Kiss L, Kruegel AC, Marek GJ, Papp M, Sporn J, Hughes ZA. GM-1020: a novel, orally bioavailable NMDA receptor antagonist with rapid and robust antidepressant-like effects at well-tolerated doses in rodents. Neuropsychopharmacology. 2024 May;49(6):905-914. doi: 10.1038/s41386-023-01783-1. Epub 2024 Jan 4. PMID: 38177696; PMCID: PMC11039472.
Andrew Carry Kruegel, WO2021134086 (to Gilgamesh Pharmaceuticals Inc, Columbia University in the City of New York).